Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals

被引：85

作者：

Herrmann, Howard C. ^{[1
]}

Lu, Jiandong ^{[2
]}

Brodie, Bruce R. ^{[3
]}

Armstrong, Paul W. ^{[4
]}

Montalescot, Gilles ^{[5
]}

Betriu, Amadeo ^{[6
]}

Neuman, Franz-Joseph ^{[7
]}

Effron, Mark B. ^{[8
]}

Barnathan, Elliot S. ^{[2
]}

Topol, Eric J. ^{[9
,10
]}

Ellis, Stephen G. ^{[11
]}

机构：

[1] Hosp Univ Penn, Philadelphia, PA 19104 USA

[2] Centocor Res & Dev Inc, Malvern, PA USA

[3] LeBauer Cardiovasc Res, Greensboro, NC USA

[4] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada

[5] Hop La Pitie Salpetriere, Paris, France

[6] Hosp Clin Barcelona, Barcelona, Spain

[7] Herz Zentrum Bad Krozingen, Bad Krozingen, Germany

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] Scripps Res Inst, La Jolla, CA 92037 USA

[10] Scripps Clin, La Jolla, CA 92037 USA

[11] Cleveland Clin Fdn, Cleveland, OH 44195 USA

来源：

JACC-CARDIOVASCULAR INTERVENTIONS | 2009年 / 2卷 / 10期

关键词：

percutaneous coronary intervention; STEMI facilitation; PRIMARY ANGIOPLASTY; NATIONAL-REGISTRY; ABCIXIMAB; THERAPY; REPERFUSION; RETEPLASE; TRIALS; SCORE;

D O I：

10.1016/j.jcin.2009.06.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives We hypothesized that patients most likely to benefit would be those at high risk with a shorter duration of acute ischemia and who required transfer for percutaneous coronary intervention (PCI). Background The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) study failed to demonstrate an improvement in the 90-day composite clinical end point of early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or abciximab alone. Methods We performed a retrospective analysis of 2,452 patients in this double-blind, placebo-controlled study. Patients were stratified by Thrombolysis In Myocardial Infarction (TIMI) risk score for ST-segment elevation myocardial infarction (STEMI), presentation to a spoke (no PCI available) or hub site, and symptom-to-randomization time. Outcomes included the primary composite end point of death, ventricular fibrillation after 48 h, cardiogenic shock, and congestive heart failure through day 90 as well as 1-year mortality. Results Mortality for all patients at 1 year was directly related to TIMI risk score (23 of 1,223 = 1.9% in patients with score < 3 and 145 of 1,229 = 11.8% with score >= 3, p < 0.001). Patients with TIMI risk score >= 3 and presentation to a spoke site with a symptom-to-randomization time <= 4 h had significantly better 1-year survival if treated with combination-facilitated PCI (hazard ratio [HR]: 0.351, p = 0.01) as well as 90-day composite outcome (HR: 0.45, p = 0.009). A trend for improved survival was also observed in patients with TIMI score >= 3 and spoke site alone (HR: 0.549, p = 0.06 Conclusions Facilitation of PCI with a combination of abciximab and half-dose reteplase improved survival at 1 year in high-risk patients presenting to a spoke hospital with symptom-to-randomization time <= 4 h. Further prospective study of facilitated PCI in this subgroup of patients is warranted. (J Am Coll Cardiol Intv 2009;2:917-24) (c) 2009 by the American College of Cardiology Foundation

引用

页码：917 / 924

页数：8

共 19 条

[1] Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients [J].